FDA Inspection 1023273 — Bloodworks

Bloodworks — FEI 3071347

The FDA completed an inspection of Bloodworks on August 17, 2017 in Seattle, WA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
August 17, 2017
Fiscal Year
2017
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
Seattle, WA (United States)